A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 176 participants.

Also called NCT02492763

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 176 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02492763
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02492763. Randomized; double masking; primary purpose treatment. Start 2015-07-27 (actual); primary completion 2017-04-18 (actual). Results posted on 2018-03-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)
Condition
Type II Diabetes Mellitus
Intervention (Drug)
MK-8521
Intervention (Drug)
Placebo
Intervention (Drug)
Liraglutide
Intervention (Drug)
Metformin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct02492763
Content hash
02f9eedd0a71f4df413966510a3565dc1fee5a7316324cf12c859f525f08a685